Cosmetic and pharmaceutical compounds for inducing the synthesis of SIRT proteins in skin and methods of use thereof
View Patent ↗A cosmetic dermo-pharmaceutical, or dermatological composition having as an active agent in an acceptable cosmetic or pharmaceutical medium, at least one compound able to activate the synthesis or SIRT proteins in skin cells.
1. A method for non-therapeutic care intended to improve appearances and general cutaneous performance of skin, comprising:
administering to the skin an effective amount of at least one compound able to activate endogenous synthesis of sirtuin (SIRT1) protein, wherein the compound is a peptide of sequence
(I):
(AA)n-Gly-Leu-Tyr-Asp-Asn-Leu-Glu-(AA)n
(AA) is any particular amino acid, and n is a whole number and ranges from 0 to 3.
2. A method to protect skin, against negative effects of UVB radiation, comprising:
administering to the skin an effective amount of at least one compound able to activate endogenous synthesis of sirtuin (SIRT1) protein, wherein the compound is a peptide of sequence
(I):
(AA)n-Gly-Leu-Tyr-Asp-Asn-Leu-Glu-(AA)n,
(AA) is any particular amino acid, and n is a whole number and ranges from 0 to 3.
3. The method according to claim 1 , wherein the compound is a peptide of sequence
Gly-Leu-Tyr-Asp-Asn-Leu-Glu.
4. The method according to claim 1 , wherein the compound is administered in the form of a composition containing cosmetically or pharmaceutically acceptable excipients.
5. The method according to claim 4 , wherein the excipients are adapted to an external topical administration.
6. A cosmetic or pharmaceutical composition wherein, in a cosmetically or pharmaceutically acceptable medium, at least one compound is able to activate the synthesis of sirtuin (SIRT1) protein in skin cells, wherein the compound is a peptide of sequence (I): (AA)n-Gly-Leu-Tyr-Asp-Asn-Leu-Glu-(AA)n, (AA) is any particular amino acid, and n is a whole number and ranges from 0 to 3.
7. The composition according to claim 6 , wherein the medium is adapted to an external topical administration.
8. The composition according to claim 6 , wherein the compound is a peptide of the sequence
Gly-Leu-Tyr-Asp-Asn-Leu-Glu.
9. The composition according to claim 6 , wherein said compound, able to activate the synthesis of SIRT1 protein, is present in an amount between about 10 −6 and 20% with respect to the total weight of the final composition.
10. The composition according to claim 6 , wherein the compound is present in the composition at a concentration ranging from about 0.05 ppm to about 500 ppm with respect to the total weight of the final composition.
11. A process or method for treating the signs of cutaneous aging, comprising applying on keratinous substrates a cosmetic composition according to claim 6 .
12. The composition according to claim 9 , wherein the compound is present in an amount between about 10 −4 and 5% with respect to the total weight of the final composition.
13. The composition according to claim 10 , wherein the compound is present, at a concentration ranging from about 0.1 ppm to about 50 ppm with respect to the total weight of the final composition.